| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Concentration | |
| Conjugate | |
| Host | |
| Immunogen | Synthetic peptide of human ATXN7 |
| Isotype | |
| Product Type | |
| Shipping | |
| Storage | |
| UniProt # |
Product Overview
The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the 'pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. This locus has been mapped to chromosome 3, and it has been determined that the diseased allele associated with spinocerebellar ataxia-7 contains 38-130 CAG repeats (near the N-terminus), compared to 7-17 in the normal allele. The encoded protein is a component of the SPT3/TAF9/GCN5 acetyltransferase (STAGA) and TBP-free TAF-containing (TFTC) chromatin remodeling complexes, and it thus plays a role in transcriptional regulation. Alternative splicing results in multiple transcript variants.
Validated Applications & Recommended Dilutions
| Application | Recommended Dilution |
|---|---|
| Immunohistochemistry | IHC 1:50-1:300 |
Antibody Specifications
| Target | ATXN7 |
|---|---|
| Host Species | Rabbit |
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Purification | Antigen Affinity Purification |
| Concentration | 0.9 mg/mL |
Immunogen
Synthetic peptide of human ATXN7 UniProt: O15265.
Species Reactivity & Cross-Reactivity
Validated for: Human, Mouse. Verify suitability in your sample type prior to use. For species or applications not listed in the datasheet, consult our technical team before purchase.
Storage & Handling
Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles.
Storage Buffer: PBS with 0.05% NaN3 and 40% Glycerol,pH7.4
Related Products
Browse additional antibodies targeting ATXN7 and complementary reagents — including secondary antibodies, blocking buffers, and detection kits — available through BioHippo.
For IHC-P, heat-induced epitope retrieval (HIER) is typically required. Recommended starting conditions: citrate buffer pH 6.0 (microwave or pressure cooker, ~20 min) for rodent samples; EDTA buffer pH 9.0 for human clinical samples. After retrieval, allow sections to cool gradually before proceeding to blocking. Include a ATXN7-positive tissue control (confirmed by literature or database expression data) and a negative isotype control in every run. Recommended dilution: IHC 1:50-1:300. Refer to the product datasheet for any target-specific retrieval guidance.
This antibody has been experimentally validated in: Human, Mouse. Cross-reactivity with other species has not been systematically evaluated. If your sample species is not listed, assess immunogen sequence homology to your target species ortholog. The immunogen used is: "Synthetic peptide of human ATXN7" — higher sequence identity between species increases the probability of cross-reactivity, but experimental validation with appropriate controls is necessary before drawing scientific conclusions.
Store at -20℃ Valid for 12 months. Avoid freeze / thaw cycles. Storage Buffer: PBS with 0.05% NaN3 and 40% Glycerol,pH7.4. To maintain antibody activity, avoid repeated freeze-thaw cycles. Aliquot into single-use volumes before first freeze. If working with the antibody frequently, keep a working stock at 4°C for up to 4 weeks — add 0.02% sodium azide to the working stock as a bacteriostatic agent if azide is not already present in the buffer. Monitor performance against a validated positive control when transitioning between storage aliquots or lots.
Polyclonal antibodies are produced from immunized animals and may exhibit some degree of lot-to-lot variation in titer, background, and sensitivity. Each production lot is tested for performance against established acceptance criteria. When transitioning to a new lot, run a side-by-side pilot comparison against your previous lot using a validated positive control sample before updating your standard protocol. If significant performance differences are observed, contact our technical support team — titer adjustments may resolve the issue in most cases.
Customization & Add-ons: Can't find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
